GLP-1s May Expand into Cancer Prevention and Treatment

Background:

GLP-1 receptor agonists are no longer just a diabetes and weight loss story. Their rapid expansion is outpacing employers’ ability to maintain affordable and sustainable pharmacy benefit programs. Some large self-funded health plans report that GLP-1 therapies now account for as much as 20% of total prescription drug spending. Yet emerging research suggests that these medications may be delivering benefits that extend far beyond weight management.

GLP-1 for cancer prevention?

A recent ASCO study found that patients receiving GLP-1 therapy were 38% to 50% less likely to develop lung, breast, colorectal, or liver cancer. Among individuals already diagnosed with prostate, pancreatic, or kidney cancer, GLP-1 use was associated with slower metastatic progression.

The common thread appears to be inflammation. GLP-1 therapies help reduce inflammatory activity, regulate insulin signaling, and may disrupt biological pathways that support tumor growth and spread.

And cancer may be only the beginning.

GLP-1 therapies are already approved for type 2 diabetes, obesity, cardiovascular disease, obstructive sleep apnea, and chronic kidney disease. Additional indications under investigation include osteoarthritis, MASH/MASLD, substance use disorders, neurological conditions, and PCOS.

What does this mean for employers?

For employers, this is no longer simply a question of managing the cost of a single drug class. It may signal a broader shift in which one category of therapy influences many of the most prevalent and costly chronic conditions within a health plan. Strategies built around the assumption that “GLP-1s are primarily diabetes drugs” may no longer reflect the evolving clinical reality.

The challenge for plan sponsors is balancing the growing body of evidence supporting GLP-1 therapies with the financial sustainability of their health plans

Is your chronic disease and pharmacy strategy keeping pace?

Sources:

• GLP-1s May Reduce Metastatic Progression of Certain Obesity-Related Cancers
• GLP-1s drive 20% of prescription spending at large self-funded plans

How Optimatum Can Help:

Optimatum Solutions partners with clients to conduct a comprehensive forensic analysis of clinical, prescription drug, and high-cost claims data to evaluate the ROI of current and potential future formulary designs and prescription drug coverage strategies.

Our goal is to help you implement the optimal solutions to improve employee health, enhance productivity, and maximize the value of your benefits investment. We also support the development of clear, effective employee communication strategies that drive understanding, engagement, and successful adoption of benefit changes.